Cary Street Partners Financial LLC Grows Position in Stryker Corporation $SYK

Cary Street Partners Financial LLC raised its stake in shares of Stryker Corporation (NYSE:SYK) by 26.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,865 shares of the medical technology company’s stock after acquiring an additional 2,045 shares during the period. Cary Street Partners Financial LLC’s holdings in Stryker were worth $3,467,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Brighton Jones LLC increased its position in shares of Stryker by 15.4% during the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after acquiring an additional 609 shares during the last quarter. Schnieders Capital Management LLC. purchased a new position in Stryker in the second quarter worth $205,000. Marshall Wace LLP grew its stake in Stryker by 107.9% in the 2nd quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock valued at $2,255,000 after purchasing an additional 77,831 shares during the period. Nebula Research & Development LLC bought a new position in Stryker in the 2nd quarter valued at $219,000. Finally, HUB Investment Partners LLC purchased a new stake in shares of Stryker during the 2nd quarter valued at $253,000. Institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling

In other news, VP M Kathryn Fink sold 5,220 shares of the business’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the completion of the transaction, the vice president directly owned 13,137 shares in the company, valued at $3,728,937.45. The trade was a 28.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.60% of the stock is currently owned by insiders.

Stryker Trading Down 2.2%

NYSE:SYK opened at $306.16 on Thursday. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $404.87. The stock’s fifty day moving average price is $323.45 and its two-hundred day moving average price is $348.79. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. The company has a market cap of $117.37 billion, a P/E ratio of 35.44, a P/E/G ratio of 1.97 and a beta of 0.80.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.38). The company had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. Stryker’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter last year, the firm posted $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, analysts expect that Stryker Corporation will post 14.98 EPS for the current year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be paid a $0.88 dividend. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s dividend payout ratio is currently 40.74%.

Wall Street Analyst Weigh In

SYK has been the topic of a number of recent analyst reports. Jefferies Financial Group reiterated a “buy” rating and set a $465.00 target price on shares of Stryker in a research note on Wednesday, March 4th. Evercore set a $355.00 price objective on shares of Stryker in a report on Friday, May 1st. Wells Fargo & Company dropped their target price on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a research note on Friday, May 1st. BTIG Research reduced their target price on shares of Stryker from $397.00 to $379.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Finally, UBS Group decreased their price target on shares of Stryker from $400.00 to $380.00 and set a “neutral” rating for the company in a research note on Tuesday, March 17th. Sixteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $395.48.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.